Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians

被引:13
|
作者
Chan, Alexandre [1 ,2 ]
Yap, Kevin Yi-Lwern [3 ]
Koh, Dorothy [1 ]
Low, Xiu Hui [1 ]
Cheung, Yin Ting [1 ]
机构
[1] Natl Univ Singapore, Dept Pharm, Fac Sci, Singapore 117543, Singapore
[2] Natl Canc Ctr Singapore, Dept Pharm, Singapore, Singapore
[3] Univ Warwick, Inst Digital Healthcare, WMG, Coventry CV4 7AL, W Midlands, England
关键词
oral anticancer drugs; antidepressants; drug-drug interactions; prevalence; co-prescription; TAMOXIFEN; CHEMOTHERAPY; INHIBITORS;
D O I
10.1002/pds.2167
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Electronic drug interaction databases are often utilized in clinical practice to detect for possible drug-drug interactions between drug pairs. It is uncertain, however, whether most of these detections interactions are clinically important in practice. To demonstrate these issues, this study utilized a comprehensive drug-drug interaction( DDI) electronic database to elucidate the prevalence of DDIs at a cancer centre between antidepressants and oral anticancer drugs( ACDs). Methods Drug utilization reports were retrieved to determine the patients who were prescribed with antidepressants oral ACDs between 2006 and 2009 at a cancer center. Medication records of these patients were retrospectively examined using OncoRx, an internet-based oncology-specific database that allows the identification of DDIs. Results Out of 910 users of antidepressants, about one-third( 281 patients, 30.9%) used an oral ACD and an antidepressant concomitantly. From these patients, about one-fifth( 21.0%) had potential DDIs. These patients were users of 17 potentially interacting drug pairs. Ten out of the 17 drug pairs could potentially cause pharmacokinetic interactions, and the rest were pharmacodynamic interactions, with only three out of the 17 drug pairs were clinically documented to cause interacting events. Conclusion The lack of screening conditions may have led to an over detection of DDI combinations by electronic DDI databases. Many of the detected interactions may not deem high significance in clinical practice. This study exposed a major weakness of current electronic DDI databases for detecting oral ACDs and antidepressants DDIs. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:939 / 947
页数:9
相关论文
共 37 条
  • [21] In vivo evaluation of pharmacokinetic drug-drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and capecitabin, and an anticoagulant, warfarin
    Hasegawa, Ai
    Tsujiya, Yoshie
    Ueda, Ayaka
    Yamamori, Motohiro
    Okamura, Noboru
    XENOBIOTICA, 2022, 52 (06) : 608 - 612
  • [22] Potential Drug-Drug Interactions Between Anti-Cancer Drugs and Other Medications in Lung Cancer Patients: A Retrospective Study
    Pinto, Rosella Ayesha
    Rao, Mahadev
    Roy, Arpita
    Thomas, Levin
    Udupa, Karthik S.
    Guddattu, Vasudeva
    CURRENT DRUG SAFETY, 2023, 18 (02) : 175 - 189
  • [23] DRUG-DRUG INTERACTIONS BETWEEN PRIMAQUINE AND SSRI/SNRI ANTIDEPRESSANTS: IMPLICATIONS FOR PRIMAQUINE CO-ADMINISTRATION WITH CYP 2D6 INHIBITORS
    Jin, Xiannu
    Potter, Brittney
    Vuong, Chau
    Luong, Thu-lan
    Xie, Lisa
    Zhang, Jing
    Zhang, Ping
    Nelson, Jennifer
    Lee, Patricia
    Sousa, Jason
    Li, Qigui
    Read, Lisa
    Pybus, Brandon
    Kreishman-Deitrick, Mara
    Smith, Philip
    Paris, Robert
    Reichard, Gregory
    Marcsisin, Sean
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2015, 93 (04): : 76 - 76
  • [24] The Potential Clinical Implications and Importance of Drug Interactions Between Anticancer Agents and Cannabidiol in Patients With Cancer
    Opitz, Brandon J.
    Ostroff, Marissa L.
    Whitman, Arin C.
    JOURNAL OF PHARMACY PRACTICE, 2020, 33 (04) : 506 - 512
  • [25] Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases
    Oda Plasencia-Garcia, Beatriz
    Isabel Rico-Rangel, Maria
    Rodriguez-Menendez, Gonzalo
    Rubio-Garcia, Ana
    Torello-Iserte, Jaime
    Crespo-Facorro, Benedicto
    PHARMACOPSYCHIATRY, 2022, 55 (01) : 40 - 47
  • [26] Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
    Beatriz Oda Plasencia-García
    Gonzalo Rodríguez-Menéndez
    María Isabel Rico-Rangel
    Ana Rubio-García
    Jaime Torelló-Iserte
    Benedicto Crespo-Facorro
    Psychopharmacology, 2021, 238 : 329 - 340
  • [27] Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
    Plasencia-Garcia, Beatriz Oda
    Rodriguez-Menendez, Gonzalo
    Rico-Rangel, Maria Isabel
    Rubio-Garcia, Ana
    Torello-Iserte, Jaime
    Crespo-Facorro, Benedicto
    PSYCHOPHARMACOLOGY, 2021, 238 (02) : 329 - 340
  • [28] Identification of potential drug-drug interactions between antiretroviral drugs from prescriptions in the private health-care sector in South Africa
    Katende-Kyenda, N. L.
    Lubbe, M. S.
    Serfontein, J. H. P.
    Truter, I.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2012, 23 (03) : 166 - 172
  • [29] The Relationship between Number of Drugs and Potential Drug-Drug Interactions in the ElderlyA Study of Over 600 000 Elderly Patients from the Swedish Prescribed Drug Register
    Kristina Johnell
    Inga Klarin
    Drug Safety, 2007, 30 : 911 - 918
  • [30] The relationship between number of drugs and potential drug-drug interactions in the elderly - A study of over 600 000 elderly patients from the Swedish prescribed drug register
    Johnell, Kristina
    Klarin, Inga
    DRUG SAFETY, 2007, 30 (10) : 911 - 918